<DOC>
	<DOCNO>NCT02532998</DOCNO>
	<brief_summary>This Phase I , Randomized , Single-Blind , Crossover Study Assess Pharmacodynamics AZD9977 follow Single-Dose administration healthy male subject</brief_summary>
	<brief_title>A Study Assess Pharmacodynamic Effect Single Doses AZD9977 Healthy Male Subjects</brief_title>
	<detailed_description>This study phase I study assess pharmacodynamics AZD9977 follow single-dose administration healthy male subject . It single-blind ( regard AZD9977 AZD9977 Placebo ) , randomize , four-treatment , four-period crossover design , potential 5th 6th randomized cross-over treatment period . In study eplerenone use positive control fludrocortisone use challenge agent . In addition safety , tolerability pharmacokinetics assess .</detailed_description>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Fludrocortisone</mesh_term>
	<criteria>Inclusion criterion 1 . Provision sign date write informed consent prior study specific procedure . 2 . Healthy male subject age 18 50 year suitable vein cannulation repeat venipuncture . 3 . Male subject must accept comply restriction sexual activity provide . 4 . Have body mass index ( BMI ) 18 30 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . 5 . Optional : Provision sign date write informed consent genetic research . Note : Participation exploratory biomarker research mandatory . If subject decline participate genetic component study , penalty loss benefit subject . The subject exclude aspect study describe protocol . 6 . Able understand , read speak English language . Exclusion criteria 1 . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . 2 . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first dose investigational medicinal product ( IMP ) . 4 . Any clinically significant abnormality hematology , clinical chemistry urinalysis result , judged investigator . 5 . Abnormal finding vital sign , 10 minute rest supine position , define follow : Systolic blood pressure ( SBP ) &lt; 90 mmHg ≥ 140 mmHg Diastolic blood pressure ( DBP ) &lt; 50 mmHg ≥ 90 mmHg Pulse &lt; 45 &gt; 85 beat per minute ( bpm ) 6 . Any clinically significant abnormality 12lead electrocardiogram ( ECG ) , judge investigator . 7 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 8 . Known suspected history drug abuse , judge investigator . 9 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first dose . The period exclusion begin 3 month final dose one month last visit whichever long . Note : Subjects consent screen , randomize study previous phase I study , exclude . 10 . Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . 11 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD9977 . 12 . Current smoker smoke used nicotine product within previous 3 month . 13 . Positive screen drug abuse , alcohol cotinine screen admission study center . 14 . Use drug enzyme induce property St John 's Wort within 3 week prior first dose . 15 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first dose , long medication long halflife . 16 . Known suspected history alcohol drug abuse excessive intake alcohol , judge investigator . 17 . Involvement AstraZeneca study site employee close relative . 18 . Subjects previously receive AZD9977 . 19 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 20 . Known allergy eplerenone fludrocortisone constituent ( include lactose , constituent Florinef™ ) . 21 . History galactose intolerance . 22 . Any infection risk infection ( surgery , trauma , significant infection ) within 90 day screen , history skin abscess within 90 day screen . 23 . Presence , history family history long QT syndrome , hypokalemia , hyperkalemia Torsades de Pointes . 24 . Serum potassium &lt; 3.5 mmol/L ≥ 5.0 mmol/L screen admission study center . 25 . Presence history active peptic ulcer . 26 . History psychiatric disorder ( include affective , psychotic , behavioral , irritability , anxiety , sleep disturbance cognitive disorder ) require specialist psychiatric review . 27 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea chocolate ) judge investigator . 28 . Subjects vegans medical dietary restriction ( vegetarian may include study ) . 29 . Subjects communicate reliably investigator . 30 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . 31 . In addition , follow regarded criterion exclusion genetic research : Previous bone marrow transplant . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>AZD9977</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Eplerenone</keyword>
	<keyword>Fludrocortisone</keyword>
</DOC>